Browsing Harvard Medical School by Keyword "Immune checkpoint blockade"

Now showing items 1-2 of 2

    • Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma 

      Cooper, Zachary A.; Reuben, Alexandre; Spencer, Christine N.; Prieto, Peter A.; Austin-Breneman, Jacob L.; Jiang, Hong; Haymaker, Cara; Gopalakrishnan, Vancheswaran; Tetzlaff, Michael T.; Frederick, Dennie T.; Sullivan, Ryan J.; Amaria, Rodabe N.; Patel, Sapna P.; Hwu, Patrick; Woodman, Scott E.; Glitza, Isabella C.; Diab, Adi; Vence, Luis M.; Rodriguez-Canales, Jaime; Parra, Edwin R.; Wistuba, Ignacio I.; Coussens, Lisa M.; Sharpe, Arlene H.; Flaherty, Keith T.; Gershenwald, Jeffrey E.; Chin, Lynda; Davies, Michael A.; Clise-Dwyer, Karen; Allison, James P.; Sharma, Padmanee; Wargo, Jennifer A. (Taylor & Francis, 2016)
      ABSTRACT We have made major advances in the treatment of melanoma through the use of targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing and sequence ...

    • Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma 

      Marmarelis, Melina E.; Davis, Meredith R.; Sethi, Nilay S.; Krajewksi, Katherine M.; McKay, Rana R.; Choueiri, Toni K.; Ott, Patrick A. (BioMed Central, 2016)
      Blockade of the immunological checkpoint programmed death 1 (PD-1) using monoclonal antibodies has shown robust anti-tumor activity across a broad range of solid and hematological malignancies including melanoma and renal ...